FDA instructs Amgen to pull Enbrel ads

02/22/2005 | NYTimes.com

The FDA ordered Amgen to pull its television ads for Enbrel, indicated for psoriasis, on grounds the advertisement did not disclose risks or mention the drug was indicated only for "chronic moderate to severe plaque psoriasis," and not milder forms. The agency also told the company its ad overstated Enbrel's effectiveness. An Amgen spokeswoman said the ad has been pulled and the company is reviewing the letter.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC